目的探讨胃肠道间质瘤的临床病理特点及治疗方法。 方法回顾性分析我院2005年7月至2010年7月期间收治的35例患者的临床资料。 结果35例患者病变分别位于胃部18例（51.4%），其中胃体15例（42.9%）、胃窦3例（8.6%）； 回肠16例（45.7%）； 小肠系膜根部1例（2.9%）。 35例均进行手术治疗，其中行胃楔形切除术15例（42.9%），胃大部切除术3例（8.6%），小肠部分切除术16例（45.7%），肠系膜肿块切除加大部分小肠切除术1例（2.9%）。 术后病理报告均为间质瘤； 免疫组织化学染色结果： CD117阳性33例(94.3%)，CD34阳性26例(74.3%)。 35例术后均获随访，随访时间6个月至5年，平均25.6个月。 1例术后10个月死于肿瘤复发，1例术后4个月死于短肠综合征、营养不良，余33例无肿瘤复发。 结论胃肠道间质瘤确诊依赖于病理组织学检查及免疫组化染色，完整切除病灶是最有效的治疗手段。
ObjectiveTo analyze the clinical efficacy of glucosamine hydrochloride in the treatment of lumbar facet joint osteoarthritis, in order to provide the most appropriate treatment for lumbar facet joint osteoarthritis. MethodsA total of 120 patients with lumbar facet joint osteoarthritis and low back pain treated between August 2014 and August 2015 were randomly divided into three groups with 40 in each. Group A was treated with glucosamine hydrochloride; group B accepted loxoprofen-sodium; and group C was given glucosamine hydrochloride plus loxoprofen-sodium. The courses of treatment were all 8 weeks in the three groups. Follow-up lasted for 16 weeks. Oswestry disability index (ODI) and visual analogue score (VAS) of the patients were compared before treatment, 8 weeks after treatment, and 8 weeks after withdrawal. ResultsThree patients in group B gave up treatment due to upper gastrointestinal moderate pain after taking the drug. Another 12 patients in group B suffered from upper gastrointestinal mild discomfort, and the symptoms alleviated after accepting symptomatic treatment. There were no drug-related adverse reactions in group A and C. A total of 117 patients completed the 8-week treatment and were all followed up. Before treatment, the ODI scores and VAS scores were not significantly different among the groups (P>0.05). After treatment, the scores changed significantly in all the groups (P<0.05). At week 8 after treatment, the clinical efficacy in group B and C was superior to that in group A, and the differences were statistically significant (P<0.05), but there was no significant difference between group B and C (P>0.05). Eight weeks after withdrawal, the clinical efficacy in group A and C was better than that in group B, and the differences were statistically significant (P<0.05), but there was no significant difference between group A and C (P>0.05). ConclusionGlucosamine hydrochloride is effective for low back pain caused by lumbar facet joint osteoarthritis, which has no non-steroidal anti-inflammatory drug-related complications. It is worthy of clinical application.
ObjectiveTo explore the correlation of serum neutrophil gelatinase-associated lipocalin (sNGAL) with inflammatory response in patients with community-acquired pneumonia (CAP) and assess the diagnostic value of sNGAL for severe CAP (SCAP).MethodsFrom January 2018 to June 2019, a total of 85 patients with CAP were enrolled in this study. Age, length of hospital stay, the levels of serum creatinine, blood urea nitrogen, white blood cell count,C-reactive protein (CRP), interleukin-6 (IL-6), and procalcitonin, and CURB-65 score were compared between patients with SCAP (n=34) and patients without SCAP (n=51). The correlations of sNGAL with serum creatinine, blood urea nitrogen, white blood cell count, CRP, IL-6, procalcitonin, and CURB-65 score were assessed with Spearman’s correlation analysis. The area under the receiver operating characteristic (ROC) curve for sNGAL diagnosing SCAP was examined. ResultsCompared with patients without SCAP, SCAP patients demonstrated older age, longer hospital stay, higher serum CRP and IL-6 concentritions, and higher CURB-65 score (P<0.05). The Spearman’s correlation test showed that sNGAL was positively correlated with serum CRP, IL-6, PCT and CURB-65 score (rs=0.472, 0.504, 0.388, and 0.405, respectively; P<0.01). According to ROC analysis, the area under curve of sNGAL for diagnosing SCAP were 0.816, with a sensitivity of 76.56% and a specificity of 74.4% when the cut-off value was 171.0 ng/mL.ConclusionssNGAL concentration is positively correlated with the serverity of CAP. It can be regarded as a reliable indicator for diagnosis of SCAP in patients with CAP.